IL32 and primary cutaneous T-cell non-Hodgkin lymphoma: Finally, IL-32 has been shown to promote the proliferation and survival of malignant CTCL cells via NF-κB- and mitogen-activated protein kinase (MAPK)-dependent mechanisms [64, 65].